Clinical and laboratory studies with tobramycin.
D000328:Adult; D000617:Aminoglycosides / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use; D001407:Bacillus / Q000187:drug effects; D002986:Clinical Trials as Topic; D004357:Drug Synergism; D004926:Escherichia coli / Q000187:drug effects; D004927:Escherichia coli Infections / Q000188:drug therapy; D005839:Gentamicins / Q000494:pharmacology; D006207:Half-Life; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007710:Klebsiella Infections / Q000188:drug therapy; D008297:Male; D008826:Microbial Sensitivity Tests; D011511:Proteus / Q000187:drug effects; D011552:Pseudomonas Infections / Q000188:drug therapy; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D018805:Sepsis / Q000188:drug therapy; D012706:Serratia marcescens / Q000187:drug effects; D013210:Staphylococcus / Q000187:drug effects; D013291:Streptococcus / Q000187:drug effects; D013997:Time Factors; D014552:Urinary Tract Infections / Q000188:drug therapy
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D005839:Gentamicins